Zynerba Pharmaceuticals, Inc.

zynerba.com

USA

80 W. Lancaster Avenue Suite 300 Devon, PA 19333

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications, including refractory epilepsy, Fragile X syndrome (FXS), osteoarthritis (OA), fibromyalgia and peripheral neuropathic pain. The Company’s ZYN002 is the synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. ZYN002 is being developed as a clear, odorless gel that is designed to provide controlled drug delivery with once- or twice-daily dosing. The Company’s ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. The transdermal patch is a non-invasive and non-oral dosage form of method of delivery. ZYN001 is a pro-drug, which is a drug administered in an inactive or less active form.